4/16
09:00 am
gral
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
Low
Report
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
4/15
09:00 am
gral
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
Low
Report
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
4/11
01:00 am
gral
Medium
Report
4/10
08:00 am
gral
GRAIL (GRAL) is now covered by Piper Sandler. They set a "neutral" rating and a $54.00 price target on the stock.
Medium
Report
GRAIL (GRAL) is now covered by Piper Sandler. They set a "neutral" rating and a $54.00 price target on the stock.
4/10
08:00 am
gral
GRAIL (GRAL) is now covered by Mizuho. They set a "neutral" rating and a $58.00 price target on the stock.
Medium
Report
GRAIL (GRAL) is now covered by Mizuho. They set a "neutral" rating and a $58.00 price target on the stock.
4/8
10:29 am
gral
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm
Low
Report
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm
4/7
04:01 pm
gral
GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide
Medium
Report
GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide
4/3
03:18 pm
gral
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm
Medium
Report
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm
4/1
03:36 pm
gral
Grail partnering with Superpower to offer Galleri cancer early detection test [Seeking Alpha]
Low
Report
Grail partnering with Superpower to offer Galleri cancer early detection test [Seeking Alpha]
4/1
01:09 pm
gral
Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection
Low
Report
Cancer Is Striking Earlier -- Superpower and GRAIL Are Partnering to Expand Early Detection
4/1
09:00 am
gral
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
Low
Report
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
3/30
11:29 am
gral
GRAIL (GRAL) had its price target lowered by Guggenheim from $130.00 to $75.00. They now have a "buy" rating on the stock.
Low
Report
GRAIL (GRAL) had its price target lowered by Guggenheim from $130.00 to $75.00. They now have a "buy" rating on the stock.
3/26
09:00 am
gral
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
Low
Report
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
3/25
09:00 am
gral
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
Medium
Report
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
3/19
09:00 am
gral
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
Medium
Report
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
3/18
09:00 am
gral
LEVI & KORSINSKY, LLP: GRAIL (GRAL) GUIDED TO 2030 CASH RUNWAY WHILE KEY TRIAL RISK WENT UNADDRESSED
Low
Report
LEVI & KORSINSKY, LLP: GRAIL (GRAL) GUIDED TO 2030 CASH RUNWAY WHILE KEY TRIAL RISK WENT UNADDRESSED
3/18
08:22 am
gral
GRAIL (GRAL) was upgraded by TD Cowen from "hold" to "buy". They now have a $65.00 price target on the stock.
Low
Report
GRAIL (GRAL) was upgraded by TD Cowen from "hold" to "buy". They now have a $65.00 price target on the stock.
3/12
04:44 pm
gral
GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor [Yahoo! Finance]
Low
Report
GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor [Yahoo! Finance]
3/12
04:30 pm
gral
GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor
Low
Report
GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor
3/12
09:00 am
gral
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
Low
Report
Levi & Korsinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed
3/4
02:15 pm
gral
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
Low
Report
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
3/2
04:01 pm
gral
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3/1
10:05 am
gral
BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment [Yahoo! Finance]
Low
Report
BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment [Yahoo! Finance]
2/24
04:02 pm
gral
GRAIL to Present at the TD Cowen 46th Annual Health Care Conference
Medium
Report
GRAIL to Present at the TD Cowen 46th Annual Health Care Conference
2/24
09:02 am
gral
GRAIL (NASDAQ:GRAL) was given a new $60.00 price target on by analysts at Morgan Stanley.
High
Report
GRAIL (NASDAQ:GRAL) was given a new $60.00 price target on by analysts at Morgan Stanley.